Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Reviva Pharmaceuticals Holdings Inc.

Alliance Global Partners analyst James Molloy reiterated a Buy rating on Reviva Pharmaceuticals Holdings on November 14 and set a price target of $...

Current Quarter	$-0.06	Next Quarter	$-0.06
Current Year	$-0.37	Next Year	$-0.19
QoQ Growth	+0.0%	YoY Growth	+48.6%
3Y EPS CAGR	N/A	Target Price	$5.00
Consensus	Buy	Upside	+624.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVPH	$0.69	-5.45%	5.60M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RVPH	$0.69	-5.5%	5.60M
3
4
5
6

RVPH

RVPH

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Reviva Pharmaceuticals Holdings Inc. Data in Excel

Get Reviva Pharmaceuticals Holdings Inc. Data in Excel